Myeloproliferative diseases is a term used for a cluster of illnesses. These diseases are when the bone marrow creates more red/white blood cells or platelets then the body needs. Polycythemia vera, essential thrombocythemia, and primary myelofibrosis together comprise the majority of myeloproliferative diseases.
The total number of people living with myeloproliferative diseases (prevalence rate) in the US is estimated to be 29,5709. This estimation is based on 2010 information.
In the US Medicare population, 53.2% of patients with essential thrombocythemia (ET) survive after 5 Years. This means out of 100 patients with essential thrombocythemia (ET), about 53 patients have survived the disease for 5 years. In the US Medicare population, 53.1% of patients with polycythemia vera (PV) survive after 5 Years. This means out of 100 patients with polycythemia vera (PV), about 53 patients have survived the disease for 5 years. In the US Medicare population, 18.2% of patients with myelofibrosis (MF) survive after 5 years. This means out of 100 patients with myelofibrosis (MF), about 53 patients have survived the disease for 5 years.
There are certain risk factors that can increase the chances of having Myeloproliferative Diseases.
There are certain symptoms and signs showing that a patient may have myeloproliferative disease. Patients may have anemia, shortness of breath with activity, loss of strength or tiredness, paleness, reduction in hunger, prolonged bleeding from minor cuts due to low platelet counts, purpura-black/blue pinpoint marks on the skin where bleeding has occurred under the skin, sinus-skin/urinary infections owing to a reduced number of low white blood cells that fight infection.
Myeloproliferative disease typically cannot be cured. Treatment typically tries to fix the irregular blood tests. If a patient has no symptoms, with a doctor’s consultation, the patient may decide to take the watchful waiting approach. This means the patient will not be on treatment but they will get frequent evaluations and undergo diagnostic checks to monitor the progress of their disease.
“Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version.” National Institutes of Health National Cancer Institute, 2019. https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq.
“Prevalence.” MPN Research Foundation, 2019. https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq.
“Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN).” Price et al. 2019.
“Myeloproliferative Neoplasms” Cancer Network-Oncology, 2019
“Myeloproliferative Disorders Signs and Symptoms” University of California San
“Treatment Options” Seattle Cancer Care Alliance, 2019.
Web links about Myeloproliferative Disorders
Chronic Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version
Overview of Myeloproliferative Disorders
Drugs Approved for Myeloproliferative Neoplasms
Chronic myeloproliferative disorders